Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04965792 · ClinicalTrials.gov registry record
Post-treatment Surveillance in HPV+ Oropharyngeal SCC
A clinical trial of Hpv and Oropharyngeal Squamous Cell Carcinoma, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT04965792: Active study of Hpv and Oropharyngeal Squamous Cell Carcinoma, sponsored by Dana-Farber Cancer Institute.
NCT04965792 is a study of Hpv and Oropharyngeal Squamous Cell Carcinoma that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 150 participants, below the 2,235-participant average among 24 other Hpv trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04965792, a study of Hpv and Oropharyngeal Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
In this research study the investigators are examining a blood test to detect HPV DNA in the blood that can possibly detect cancer recurrence earlier than with standard surveillance measures.
Primary Outcome
The proportion of patients with recurrence first detected by ctHPV DNA will be calculated as a percentage and 95% confidence intervals (CI) established using binomial exact calculation.
Conditions Studied
Interventions
- OTHER Screening
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-11-19 |
| Est. Completion | 2027-11 |
What the registry record for NCT04965792 still lists
NCT04965792 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 2,235-participant average among 24 other Hpv trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Hpv appearing as the primary indexed condition, and to 1 intervention - of which Screening is the first listed.
NCT04965792 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04965792 about?
NCT04965792 is a clinical study titled "Post-treatment Surveillance in HPV+ Oropharyngeal SCC". In this research study the investigators are examining a blood test to detect HPV DNA in the blood that can possibly detect cancer recurrence earlier than with standard surveillance measures.
What is the current status of trial NCT04965792?
This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2020-11-19. Estimated completion is 2027-11.
What conditions does trial NCT04965792 study?
This clinical trial studies the following conditions: Hpv, Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04965792?
The interventions under investigation include: Screening (OTHER).
Who is sponsoring clinical trial NCT04965792?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04965792 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hpv
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04965792's enrollment target sits among peer trials
150 15th of 24 higher than 10 of 24 other Hpv trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hpv trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination
RECRUITING · NA
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
RECRUITING · Phase 2
-
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
RECRUITING
-
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
RECRUITING · Phase 2
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI